GCG and diabetic cardiomyopathy: It will be essential for future preclinical studies to also elucidate how these other factors may influence diastolic function either synergistically or negatively when combined with SGLT2 inhibitors or incretin-based therapies, in order to understand the true translational potential of these therapies specifically for diabetic cardiomyopathy.